drugset / Trial / NCT00066157
Alzheimer's Disease: Therapeutic Potential of Estrogen
Phase 2/3
Completed
42 enrolled
University of Wisconsin, Madison
National Institute on Aging (NIA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.
Timeline
- Start
- 2001-09
- Primary completion
- 2007-12
- Completion
- 2007-12
Publications
- Background Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging. 2002;19(6):405-27. doi: 10.2165/00002512-200219060-00002.
- Background Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001 Aug 28;57(4):605-12. doi: 10.1212/wnl.57.4.605.
- Background Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999 Aug;24(6):657-77. doi: 10.1016/s0306-4530(99)00020-7.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 50 ug | Other |
| Subject | Estradiol | Other / unclassified | 100 ug | Other |
| Subject | medroxyprogesterone acetate | Other / unclassified | 2.5 mg | — |